Image Analysis Group (IAG), known for its expertise in clinical trial imaging and AI-driven biomarker development, has expanded its footprint in the United States by launching a new office in Cambridge, Massachusetts. This strategic move positions the company closer to the heart of the region’s vibrant biotechnology and pharmaceutical sectors, enhancing opportunities for collaboration and local support for clinical trials.
The Cambridge office will enable IAG to work more intimately with biotech companies, pharmaceutical firms, and contract research organizations involved in Phase I–III clinical trials and projects requiring intensive imaging. By being in proximity to these entities, IAG aims to bolster its partnerships and provide tailored support across various therapeutic areas, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic disorders.
In addition to strengthening industry ties, the new location is set to create new job opportunities in the region. Over the next 12 to 24 months, IAG plans to hire personnel in clinical imaging operations, data science, regulatory support, and business development to support its expanding services. The office will facilitate IAG’s comprehensive imaging services, which include clinical trial design consultation, imaging protocol refinement, centralized image analysis, and regulatory-compliant data management.
With its new presence in the Boston life sciences ecosystem, IAG anticipates improved collaboration with a range of stakeholders, including biotechnology companies, pharmaceutical organizations, academic institutions, and clinical research centers. This expansion aligns with IAG’s global strategy, which involves supporting clinical trials across North America, Europe, and the Asia-Pacific region, ensuring standardized imaging protocols and consistent data analysis on a worldwide scale.
Founded in 2007 and headquartered in London, Image Analysis Group (IAG) operates as an imaging Clinical Research Organization (iCRO), specializing in imaging-based clinical trial endpoints. The company’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight. Through its global operations, IAG collaborates with pharmaceutical, biotechnology, and medtech companies to advance multi-center clinical studies. For more information, visit their website at www.ia-grp.com or contact them via email at [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.